[
  {
    "ts": null,
    "headline": "Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion",
    "summary": "Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery system. Management boosted full-year guidance as business momentum remains strong. See our latest analysis for Insulet. Insulet’s latest breakout results have built on a year of steadily improving sentiment, powering the stock to a 24.5% year-to-date share price return and a robust 19.3% total...",
    "url": "https://finnhub.io/api/news?id=a0aaf9bd62beb23b197a697c7bed199cc9c57cb33cd68f71b750e6bd9b62e323",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762589539,
      "headline": "Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion",
      "id": 137378640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery system. Management boosted full-year guidance as business momentum remains strong. See our latest analysis for Insulet. Insulet’s latest breakout results have built on a year of steadily improving sentiment, powering the stock to a 24.5% year-to-date share price return and a robust 19.3% total...",
      "url": "https://finnhub.io/api/news?id=a0aaf9bd62beb23b197a697c7bed199cc9c57cb33cd68f71b750e6bd9b62e323"
    }
  }
]